Inflammatory Bowel Disease Cohort in Nantes

Nantes University Hospital360 enrolled

Overview

The CELESTE cohort will be a three-center prospective cohort associated with the creation of a biobank including Inflammatory Bowel Diseases (IBD) patients with active disease

The CELESTE cohort will be a prospective cohort of IBD patients followed up at Nantes University Hospital, Jules Verne Clinic (Nantes) and/or Confluent Private Hospital (Nantes). The multicentric nature of the cohort including a tertiary referral center and two secondary care centers is a major asset, enabling the enrolment of a broad spectrum of patients, from those naïve to any immunomodulatory treatment to those refractory to multiple biologic therapies. It will be associated with a multi-omics biobank with the aim of identifying new cellular and molecular signatures of success of the therapeutic strategy at one year.

Study Type

OBSERVATIONAL

Enrollment

360

Conditions

Inflammatory Bowel Diseases

Interventions

Collection of biological samplesOTHER

Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 18 years of age; * Patients with an established diagnosis of IBD: CD, UC, unclassified IBD or refractory chronic pouchitis; * Patients with active disease requiring surgery or endoscopy, whether performed at diagnosis or prior to initiation of new therapy; * Patients who have given written consent to participate in the study and to keep biological samples for research purposes Exclusion Criteria: * Patients refusing to participate in the cohort; * Patients with chronic inflammatory bowel disease quiescent at inclusion; * Patients with a contraindication to general anaesthesia; * Vulnerable patients (under court protection, curators, guardians);

Locations (3)

CHU de Nantes

Nantes, France

RECRUITING

Clinique Jules Verne

Nantes, France

NOT_YET_RECRUITING

Hopital Privé du Confluent

Nantes, France

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Proportion of patients who succeed in their therapeutic strategy

Determine the proportion of patients who succeed in their therapeutic strategy at one year

Time frame: One year after inclusion

Central Contacts

Catherine Le Berre, MD

CONTACT

+33240083152 catherine.leberre@chu-nantes.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.